Cracking The Code: Understanding Analyst Reviews For Quest Diagnostics
Portfolio Pulse from Benzinga Insights
In the past three months, 7 analysts have provided ratings for Quest Diagnostics (NYSE:DGX), with most being indifferent. The average 12-month price target has increased to $149.71. Analysts have raised their price targets, reflecting a positive outlook. Quest Diagnostics shows strong financial performance with notable net margins, ROE, and ROA, and a healthy debt-to-equity ratio.
July 05, 2024 | 3:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quest Diagnostics has received mostly indifferent ratings from analysts over the past three months, with a recent increase in the average 12-month price target to $149.71. Analysts have raised their price targets, indicating a positive outlook. The company shows strong financial performance with high net margins, ROE, and ROA, and a healthy debt-to-equity ratio.
The increase in the average price target and the positive adjustments by multiple analysts suggest a favorable short-term outlook for Quest Diagnostics. The company's strong financial metrics further support this positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100